Drugmaker Moderna lays out plans to test COVID-19 vaccine
September 18, 2020
The biotech company Moderna released a 135-page document Thursday that spells out the details of how it is conducting the late-stage trial of its coronavirus vaccine, and how safety and efficacy will be determined.
The document suggests that the first analysis of the trial data may not be conducted until late December, and that there may not be enough information then to determine whether the vaccine works. Subsequent analyses, scheduled for March and May, are more likely to provide an answer.
Those timelines mesh with the cautionary estimates from many researchers, and stand in sharp contrast to President Donald Trump's predictions that a vaccine will become widely available before the end of this year.